Completely agree with your response here and want to thank you for providing the comment. I've been in Advaxis for some time now and patience is not the issue for me. I do have a concern that Advaxis will get passed up as immunotherapy continues to evolve and gain popularity. This concern stems from a number of factors with a main one being BPs that are moving forward with their own immunotherapy platforms. As a result, they may not have a need for Advaxis and therefore resulting in the market not having a need for Advaxis. Example, Merck (Keytruda) and BMY (Opdivo) already being to market -- further, we are still in clinicals with our H&N treatment while BMY has a PDUFA for H&N set for this coming November. Big BP has and may continue to get into the market well before Advaxis and by the time Advaxis gets there...how does the company plan/intend to beat out the bigger players.
News 
Market Data 
Discover 
